ELTX Stock Analysis: Buy, Sell, or Hold?
ELTX - Elicio Therapeutics, Inc. Common Stock
$10.65
-0.01 (-0.09%)
▼
5d:
-1.57%
30d:
-12.42%
90d:
+33.79%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ELTX is down 7.6% this week, but smart money is accumulating calls. Top strike: $15 2026-05-15 with 47 OI. Call ratio: 100% View Scanner →
Strength: 8.8/10
Get Alerted When ELTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ELTX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: ELTX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: ELTX is currently trading at $10.65, which is considered oversold relative to its 30-day fair value range of $10.66 to $12.44.
Technical Outlook: Technically, ELTX is in a uptrend. Immediate support is located at $9.91, while resistance sits at $12.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.50 (+64.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELTX is in a uptrend. Immediate support is located at $9.91, while resistance sits at $12.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (14th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.50 (+64.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$10.66 -
$12.44
Company Quality Score
54/100
(HOLD)
Options IV Signal
14th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 14th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 64.3% below Wall St target ($17.50)
Fair Price Analysis
30-Day Fair Range
$10.66 -
$12.44
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.26
(30.6%)
Support & Resistance Levels
Support Level
$9.91
Resistance Level
$12.00
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.61
Wall Street Target
$17.50
(+64.3%)
Share & Embed Analysis
Last updated: April 05, 2026 5:00 PM ET
Data refreshes hourly during market hours. Next update: 6:00 PM
Data refreshes hourly during market hours. Next update: 6:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$138 | 61 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
